CAPS2
protein-codingcalcyphosine 2, the group of EF-hand domain containing
Gene summary
Calcyphosine-2 is a calcium-binding protein with 2 EF-hand motifs (Wang et al., 2002 [PubMed 11846421]).[supplied by OMIM, Mar 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~114.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0100038
Submitter: LiferaOmics
Genetic evidence – Published: PMID: 37644014 — One proband from a consanguineous family, homozygous for NM_032606.5:c.1490_1491del (predicted loss-of-function); AR inheritance; intellectual disability/neurodevelopmental disorder; no reported segregation; no case-control data. Case-level points (default for predicted null in AR disease) = 1.0 (AR predicted/proven null = 1.5, −0.5 downgrade for homozygosity/consanguinity); segregation = 0; case-control = 0. PMID: 27431290 — One proband from a consanguineous family, homozygous for NM_032606.5:c.1490_1491del (predicted loss-of-function); AR inheritance; intellectual disability/neurodevelopmental disorder; no reported segregation; no case-control data. Case-level points (default for predicted null in AR disease) = 1.0 (AR predicted/proven null = 1.5, −0.5 downgrade for homozygosity/consanguinity); segregation = 0; case-control = 0. Published genetic evidence total = 2.0 / 12 Genetic evidence – Our cases: Case 1 — One proband with homozygous NM_001286548.3:c.1148A>G; p.(Ter383Trpext*) (predicted loss-of-function); motor delay and dysmorphic features; positive consanguinity; similarly affected sibling reported but not genotyped; no segregation data; no case-control data. Case-level points (default for predicted null in AR disease) = 1.0 (AR predicted/proven null = 1.5, −0.5 downgrade for homozygosity/consanguinity); segregation = 0; case-control = 0. Case 2 — One proband with homozygous NM_001286548.3:c.1148A>G; p.(Ter383Trpext*) (predicted loss-of-function); autism spectrum disorder, intellectual disability, severe speech delay, epilepsy in remission; positive consanguinity; affected sibling reported but not genotyped; no segregation data; no case-control data. Case-level points (default for predicted null in AR disease) = 1.0 (AR predicted/proven null = 1.5, −0.5 downgrade for homozygosity/consanguinity); segregation = 0; case-control = 0. Our cases contribution = 2.0 / 12 Total genetic evidence (published + current) = 4.0 / 12 Experimental evidence – Published: PMIDs: 17380209, 19238500, 21173225 — Functional and animal model data demonstrating CADPS2 involvement in dense-core vesicle exocytosis and neurotrophin release, with knockout mouse models showing neurodevelopmental and behavioral abnormalities consistent with ASD/ID spectrum. Functional role in neuronal secretion = 1.0; animal model phenotypic overlap = 2.0. Experimental evidence total = 3.0 / 6 Overall score (with current cases) = 7.0
Inheritance Pattern: AR
Disease ID:MONDO:0001071
Submitter: Ambry Genetics
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CAPS2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001355024.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 2 | 3 | |||
| missense | 80 | 4 | 1 | 85 | ||
| nonsense | 0 | |||||
| start loss | 1 | 1 | ||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 4 | 4 | ||||
| Total | 0 | 0 | 86 | 4 | 3 | 93 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001341953.2 | 16 | MANE Select | |
| Ensembl | ENSP00000514274.1 | 16 | MANE Select | |
| RefSeq | NP_001273476.1 | 15 | Standard | |
| RefSeq | NP_001273477.1 | 11 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Molecular Function
- calcium ion binding
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000409445
- Coding exons
- 18
- Length
- 114950
- Individuals with no LoFs
- 125625
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 110
- Defined
- 125735
- p
- 0.000438
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.0866 | 271 | 267 | 1.01 | 0.0000127 | 3675 |
| Missense (PolyPhen) | 66 | 64.39 | 1.025 | 861 | ||
| Synonymous | 1.09 | 75 | 88.0 | 0.852 | 0.00000401 | 971 |
| Loss of Function | 0.0994 | 36 | 36.6 | 0.982 | 0.00000210 | 445 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00031 | 0.00031 | rare |
| Latino/Admixed American | 0.00097 | 0.00093 | rare |
| Ashkenazi Jewish | 0.0018 | 0.0017 | notable |
| East Asian | 0.00022 | 0.00022 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.00033 | 0.00033 | rare |
| South Asian | 0.00037 | 0.00036 | rare |
| Other | 0.00067 | 0.00065 | rare |
dbNSFP Gene Annotations
Source:
Recessive Scores
- pRec
- 0.0922
Intolerance Scores
- LoFtool
- 0.570
- RVIS EVS
- 0.2
- RVIS percentile EVS
- 67.3
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.410
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |